IDDI provides biostatistical and eClinical services to pharmaceutical and biotech companies since 1991.
We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.
With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
Navigate BioPharma Services delivers high quality, innovative and differentiated solutions for drug development and diagnostic applications. As a trusted partner, we support custom assay development and end-to-end clinical trial testing from sample logistics to project and data management for global clinical trials. Our broad portfolio of diverse technologies for clinical biomarker and diagnostic applications are run by specialized professionals experienced in GxP, CAP and CLIA requirements.
Biodesix® is an experienced blood-based diagnostic solutions company with a clinical focus in lung cancer. Our comprehensive diagnostic testing capabilities help our partners decipher the complexity of cancer by profiling both the tumor and immune system. Biodesix creates end-to-end solutions with our biopharma partners from initial biomarker discovery to companion diagnostic partnering, including commercialization and reimbursement.
Invivoscribe® is a comprehensive CDx partner, providing ISO 13485 compliant biomarker development, cGMP manufacturing, regulatory capability, clinical trial services, and global commercialization. It offers internationally standardized testing through ISO 15189 laboratory network (US, Europe, Asia). Its Streamlined CDx™ model has proven successful in accelerating FDA, EMA and PMDA approvals of new targeted therapies.
Rules-Based Medicine (RBM), a Q2 Solutions Company, is a CLIA certified, multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services and a novel whole blood immunophenotyping device (TruCulture®). RBM’s internally developed and manufactured immunoassays based on Multi-Analyte Profiling (MAP) and Single-Molecule Array (SimoaTM) ultrasensitive immunoassay technology provides translational and clinical researchers with reproducible and quantitative data for a few or hundreds of human proteins. The comprehensive menu provides extensive coverage of numerous pathways and delivers accurate pharmacodynamic and safety assessments. RBM’s CLIA certified biomarker testing laboratory is located in Austin, TX.
Imagia brings together healthcare expertise and advanced artificial intelligence to diagnose, treat, and cure high burden diseases. Through its EVIDENS platform, Imagia enables its stakeholders to learn from distributed healthcare data and discover AI-driven clinical solutions. Working collaboratively with hospital, biotech, pharma, and medical device partners, Imagia is on a mission to unleash the potential of all data across all organizations to achieve medical breakthroughs.
Paragon Genomics, Inc. specializes in sample preparation for targeted next-generation sequencing (NGS). We develop and commercialize reagents and molecular diagnostic tools for genomic analysis of clinically-relevant samples. Our CleanPlex® and CleanPlex® UMI NGS panels combine superior primer design and innovative library preparation chemistry to eliminate non-specific PCR products, incorporate molecular identifiers, and achieve superior target enrichment and variant detection performance.
DermTech is a leader in the new category of medicine, precision dermatology. DermTech’s mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments.
Flagship Biosciences, Inc. is a technology driven tissue analysis services company delivering the most accurate and informative data for improved drug development. The company offers a full range of tissue analysis services using its award-winning technology to deliver breakthrough contextual data supported by a team of experienced pathology and scientific experts. It caters to pharmaceutical, biotechnology, and clinical diagnostic companies. Flagship Biosciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. www.flagshipbio.com
Eutropics, a clinical diagnostics company, is developing novel, functional assays that enable personalized medicine approaches to treating cancer.
Eutropics’ PraediCare DxTM platform delivers medically useful insight that accelerates drug development and guides treatment.
Based on the principles of apoptosis biology, the Praedicare DxTM platform provides predictive functional biomarkers for liquid ad solid cancers.
The Mcl-1 Dependency Assay is a Laboratory Developed Test (LDT) for Alvocidib, and becoming a companion diagnostic for other MCL1 targeting therapies.
Headquartered in Tucson, Arizona, HTG is focused on accelerating precision medicine – from diagnosis to treatment – by harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas. HTG’s proprietary extraction-free RNA expression technology simplifies and automates complex, highly multiplexed gene expression profiling from solid and (biofluid) liquid samples, even when limited by amount and quality. HTG’s transcriptome and targeted panels are designed to enable biomarker profile assessment and gene signature development associated with disease state, treatment response and outcome.
We develop innovative immunohistochemistry (IHC) and in situ hybridization (ISH) instruments and tissue-based reagents that empower researchers. Our instrument and protocol flexibility allow for multiplex IHC, gene and protein ISH/IHC, mRNA ISH, miRNA ISH, DNA ISH, and the most challenging assays. Accelerate the discovery of new targets and biomarkers, speed assay development and target validation using DISCOVERY products.
Crown Bioscience is a cutting edge technology company providing drug discovery and services in oncology. Our diverse preclinical platform including in vitro, in vivo, ex vivo, and in silico models enables clients around the world to deliver superior clinical candidates through thorough dissection of drug mechanism of action and biomarker discovery.
Kypha is a clinical diagnostic company driven by the need for reliable and accessible diagnostic testing for immune system activation, particularly surrounding the complement system. Since its founding in 2010, Kypha’s comprehensive complement activation diagnostics program has focused on sample workflows in various clinical settings in order to reduce sample management requirements and preanalytical variability. Kypha took another step in this direction with the acquisition of Biosensia and its proprietary next generation diagnostic platform, RapiPlex, designed for low complexity, CLIA-waived protocols and multiplex assay formats for disease specific testing panels. Biosensia also brings custom assay development expertise, regulatory support, and ISO13485-certified diagnostics manufacturing services with a track record of delivering custom assays for infectious disease, autoimmunity, cancer, allergy, and drugs of abuse with support for regulatory filings
Tempus is bringing the power of artificial intelligence to healthcare by building the world’s largest library of molecular and clinical data and a platform to make that data accessible and useful. We provide genomic sequencing services and analyze molecular and therapeutic data at scale to empower physicians, researchers, and biopharma companies to make real-time, data-driven decisions.
Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets. With over 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers' most challenging questions.
Agilent brings the power of precision medicine to customers, partners, and patients. Agilent is a partner of choice to pharmaceutical and biotech companies producing innovative diagnostics and therapeutics for the benefit of patients around the world.
Champions Oncology provides an end-to-end range of research and development solutions and services, from cell lines to modeling treatment in the clinic using PDX models, that improve the productivity of oncology drug development. Using both in vitro and in vivo testing platforms, companies can leverage the expertise at Champions Oncology to help guide decision making for clinical development scenarios. Champions Oncology is your partner in meeting today’s needs and innovating for tomorrow’s challenges.
Ordinatrix builds on over a decade of development and refinement of the Nucleic Acid Programmable Protein Arrays (NAPPA) technology. Ordinatrix provides a customizable solution for analysis of the proteome with the launch of the 2nd generation NAPPA silicon nanowell ActiveArray 2.0 platform. Our just-in-time protein production process allows us to provide customers with the screening of the complete human proteome comprising over 18,000 unique proteins, or selective target proteins of their choosing.
BioIVT, formerly BioreclamationIVT, is a leading global provider of high-quality biological specimens and value-added services. We specialize in control and disease state samples including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples.
“Our mission is to create a high quality, powerful set of tools to help Life Scientists accelerate the understanding of biology and disease and apply these advances to diagnosis and treatment. Affimer® reagents are engineered affinity proteins based on a small protein scaffold that can be engineered to bind with high specificity and affinity to a range of targets. These can be used in diagnostics, drug/biomarker discovery, biotech research & development and as therapeutic agents.”
Leica Biosystems is a global leader in cancer diagnostics with the most comprehensive portfolio from biopsy to diagnosis. With unique expertise, we are dedicated to driving innovations that connect people across radiology, pathology, surgery and oncology. Our Companion Diagnostics team collaborates with leading biotechnology and pharmaceutical companies. Together, we develop and commercialize cutting-edge diagnostic test solutions that help identify patients likely to benefit from our partners’ emerging therapies, a critical element of personalized medicine.
The PointCross Xbiom™ Biomarker Workbench unifies disparate data from clinical trials and patient molecular (omics) biomarkers for search and selection of stratified cohorts with analysis, correlation and visualization of data. The Biomarker Workbench is a module within the Xbiom™ Platform and serves all phases of development from discovery assay to ex-vivo exploratory assay, in-vivo non-clinical, clinical trials, and RWE. Xbiom™ is currently used by many of the top 10 global biopharmaceuticals.
As an established IVD company, Randox Biosciences offers tailored diagnostic solutions to support faster, more effective and safe development of new drugs.
Randox have a wide range of in house capabilities, ranging from the development of novel Biomarkers; manufacture of antibodies (mAb, sdAb); production of single and multiplex IVD grade tests; quality control; provision of clinical laboratory services; regulatory expertise and worldwide distribution.
Choose Randox Biosciences as your companion diagnostic partner to ensure the safety and quality of your drug development process.
Sysmex Inostics is a global leader in plasma-based molecular diagnostics, supporting clinical trials and patient care with innovative ultra-high sensitivity SafeSEQ next-generation sequencing and OncoBEAM™ enhanced digital PCR liquid biopsy solutions. We are a trusted partner to leading pharmaceutical companies, advancing their efforts to bring the most effective cancer therapies and diagnostic solutions to global markets. Our custom solutions can be readily deployed into clinical development programs to expedite biomarker associations with treatment outcomes.
With over 15 years of experience in genetic and epigenetic clinical research, EpigenDx offers high quality products and laboratory services focused on DNA methylation analysis, gene expression profiling, and mutation analysis. Our scientific teams carefully evaluate each project and establish analysis procedures using best fit technologies, including NGS, Pyrosequencing, RT-PCR, digital PCR, and GeneChip Microarray. Our popular services include Line-1 global methylation tests and Foxp3-TSDR analysis for epigenetic immunotherapy. Our GLP compliant and CLIA certified services make us the perfect partner during pre-clinical research and diagnostic test development.
Every day, QIAGEN serves 500,000 customers globally, all seeking insights from DNA and RNA. Delivering Sample to Insight solutions for molecular testing, we help scientists and clinicians achieve breakthroughs in life sciences research, molecular diagnostics and drug development. This is how we make improvements in life possible. In healthcare and academic institutions, and drug-discovery and forensic laboratories, QIAGEN solutions advance disease detection and treatments, enable precision medicine, and aid crime detection and human identification.